NEW YORK, NY--(Marketwire - Oct 10, 2011) - The biotech industry is generating significant investor interest this year as an influx of new and lucrative therapies work their way towards regulatory approval. Although younger, unprofitable firms are having difficulty securing funding, reports suggest biotech companies with promising pipelines should be able to secure necessary capital. The Bedford Report examines the outlook for companies in the biotechnology industry and provides equity research on BioSante Pharmaceuticals, Inc. (NASDAQ: [ BPAX ]) and Sangamo Biosciences, Inc. (NASDAQ: [ SGMO ]). Access to the full company reports can be found at:

[ www.bedfordreport.com/BPAX ]

[ www.bedfordreport.com/SGMO ]

According to a recent report from Ernst & Young, US biotech companies raised $25 billion last year - a 15 percent jump over the previous year and the highest amount since 2007. Of concern is that more than 82 percent of that funding went to 20 percent of the companies. Younger, unprofitable companies in the US that depend on funding from venture capital firms, stock sales and partnerships saw available capital decline 21 percent in 2010.

The Bedford Report releases investment research on the Biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.bedfordreport.com ] and get exclusive access to our numerous analyst reports and industry newsletters.

BioSante is currently running three late-stage clinical trials of LibiGel, a female sexual dysfunction treatment. Last week the company announced completion of its two pivotal LibiGel efficacy trials, required for the company's anticipated LibiGel new drug application (NDA). In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from HSDD by 238 percent versus baseline.

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. Sangamo said it is ending development of SB-509, which was being studied as a treatment for diabetic neuropathy. The company said the drug worked about as well as it has in previous studies, but it was not significantly more effective than a placebo. It said patients who were treated with the placebo did better than expected on measurements including nerve conduction speed and impairment scores.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: [ http://www.bedfordreport.com/disclaimer.php ].